As on Wednesday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) started slowly as it slid -1.81% to $3.25, before settling in for the price of $3.31 at the close. Taking a more long-term approach, PHAT posted a 52-week range of $2.21-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 1600.29%. Meanwhile, its Annual Earning per share during the time was 12.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 42.60%. This publicly-traded company’s shares outstanding now amounts to $69.64 million, simultaneously with a float of $39.42 million. The organization now has a market capitalization sitting at $226.90 million. At the time of writing, stock’s 50-day Moving Average stood at $4.60, while the 200-day Moving Average is $9.80.
Phathom Pharmaceuticals Inc (PHAT) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Phathom Pharmaceuticals Inc’s current insider ownership accounts for 43.53%, in contrast to 59.96% institutional ownership. According to the most recent insider trade that took place on May 09 ’25, this organization’s Director bought 35,602 shares at the rate of 3.22, making the entire transaction reach 114,616 in total value, affecting insider ownership by 35,602. Preceding that transaction, on May 12 ’25, Company’s Director bought 12,601 for 3.04, making the whole transaction’s value amount to 38,301. This particular insider is now the holder of 48,203 in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
Phathom Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 42.60% and is forecasted to reach -0.32 in the upcoming year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Let’s observe the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). It’s Quick Ratio in the last reported quarter now stands at 3.54. The Stock has managed to achieve an average true range (ATR) of 0.51. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.77.
In the same vein, PHAT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.24, a figure that is expected to reach -0.90 in the next quarter, and analysts are predicting that it will be -0.32 at the market close of one year from today.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Through scrutinizing the latest numbers posted by the [Phathom Pharmaceuticals Inc, PHAT], it can be observed that its last 5-days Average volume of 4.14 million was better the volume of 1.44 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 56.69% While, its Average True Range was 0.51.
Raw Stochastic average of Phathom Pharmaceuticals Inc (PHAT) in the period of the previous 100 days is set at 16.28%, which indicates a major fall in contrast to 46.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 194.87% that was higher than 119.55% volatility it exhibited in the past 100-days period.
